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Structure of acetylcholinesterase complexed with E2020
(Aricept): implications for the design of new anti-Alzheimer drugs
Gitay Kryger1*, Israel Silman2 and Joel L Sussman1,3
Background: Several cholinesterase inhibitors are either being utilized for
symptomatic treatment of Alzheimer’s disease or are in advanced clinical trials.
E2020, marketed as Aricept, is a member of a large family of N-benzylpiperidine-
based acetylcholinesterase (AChE) inhibitors developed, synthesized and
evaluated by the Eisai Company in Japan. These inhibitors were designed on the
basis of QSAR studies, prior to elucidation of the three-dimensional structure of
Torpedo californica AChE (TcAChE). It significantly enhances performance in
animal models of cholinergic hypofunction and has a high affinity for AChE,
binding to both electric eel and mouse AChE in the nanomolar range.
Results: Our experimental structure of the E2020–TcAChE complex pinpoints
specific interactions responsible for the high affinity and selectivity
demonstrated previously. It shows that E2020 has a unique orientation along
the active-site gorge, extending from the anionic subsite of the active site, at the
bottom, to the peripheral anionic site, at the top, via aromatic stacking
interactions with conserved aromatic acid residues. E2020 does not, however,
interact directly with either the catalytic triad or the ‘oxyanion hole’, but only
indirectly via solvent molecules.
Conclusions: Our study shows, a posteriori, that the design of E2020 took
advantage of several important features of the active-site gorge of AChE to
produce a drug with both high affinity for AChE and a high degree of selectivity
for AChE versus butyrylcholinesterase (BChE). It also delineates voids within the
gorge that are not occupied by E2020 and could provide sites for potential
modification of E2020 to produce drugs with improved pharmacological profiles.
Introduction
Observations documenting adverse effects of anticholiner-
gic drugs on memory [1], taken together with postmortem
data that revealed low cholinergic activities in Alzheimer’s
disease (AD) patients [2], led to the hypothesis, known as
the ‘cholinergic hypothesis’, that AD is associated with an
impairment in cholinergic transmission [3–5]. This led to
the suggestion that cholinesterase (ChE) inhibitors would
reverse a putative deficit in acetylcholine (ACh) levels asso-
ciated with AD, and thus might reverse the memory impair-
ments characteristic of the disease [5,6]. Consequently, a
number of ChE inhibitors have been considered as candi-
dates for the symptomatic treatment of AD and have been
utilized in clinical trials. They include natural substances,
such as physostigmine [6] and huperzine A [7], both of
which are alkaloids, and synthetic compounds such as SDZ
ENA-713, also known as Exelon [8], and metrifonate [9].
Recently, evidence was presented that acetylcholinesterase
(AChE) accelerates assembly of amyloid-β-peptides into
the amyloid fibrils that form the senile plaques characteris-
tic of AD [10]. It was suggested that a hydrophobic environ-
ment close to the peripheral binding site of the enzyme, at
or near the entrance to the active-site gorge, might be
involved in this process [11].
The first, and thus far the only, two drugs approved by the
United States Food and Drug Administration (FDA) for
treatment of AD are both reversible inhibitors of AChE.
They are tacrine (THA), approved in 1993 and marketed as
Cognex® [12], and the more potent ChE inhibitor, E2020
((R,S)-1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl-
piperidine; Figure 1), also know by its trivial name done-
pezil hydrochloride and marketed as Aricept, which was
approved in 1996 [13]. E2020 is a member of a large family
of N-benzylpiperidine-based AChE inhibitors that were
developed, synthesized and evaluated by the Eisai Company
in Japan [14], on the basis of QSAR studies [15,16], prior
to elucidation of the three-dimensional (3D) structure of
Torpedo californica AChE (TcAChE) [17]. It was shown to
significantly enhance performance in animal models of
cholinergic hypofunction [18], and to have high affinity for
AChE, binding to both electric eel and mouse AChE in the
nanomolar range [19]. THA and E2020 share the same target,
but whereas THA must be administered up to four times a
day, and is associated with hepatotoxicity, slow pharmaco-
kinetics and a high incidence of side effects, E2020 offers
the patient significant improvements by being adminis-
tered only once a day and having fewer side effects. Fur-
thermore, E2020 displays high selectivity for AChE in
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comparison to butyrylcholinesterase (BChE); this may be
important, as it has been suggested that inhibition of BChE,
which is abundant in human plasma, may cause potentiat-
ing side effects [20,21]. The affinity of E2020 for human
AChE is ~1000-fold greater than for human BChE, whereas
THA has a similar affinity for the two enzymes [22,23].
Attempts to explain the specificity of E2020, and of other
Eisai inhibitors, were made originally using QSAR and by
theoretical conformational analysis. Subsequent to determi-
nation of the 3D structure of TcAChE, automated computa-
tional techniques based on the known coordinates were
employed [24,25]. Although the earlier modeling studies
attributed the differential specificity for AChE and BChE
to differences in the geometry within the active site [26],
the more recent studies suggested that E2020 and the other
Eisai compounds are oriented along the axis of the active-
site gorge and that the differential specificity can be attrib-
uted to structural differences in AChE and BChE at the top
of the gorge, at the ‘peripheral’ anionic site [14,24,25]. Our
experimental structure of the E2020–TcAChE complex
broadly confirms these latter assignments and pinpoints the
specific interactions that are responsible for the high affinity
and selectivity demonstrated previously.
Results and discussion
Overall structure
The overall structure of the E2020–TcAChE complex at
2.5 Å resolution is shown in Figure 2. The protein is dis-
played as a coil with the initial difference electron-density
map of E2020 superimposed as a ‘chicken-wire’ net. It can
be clearly seen that E2020 has a unique orientation along
the active-site gorge, extending from the anionic subsite of
the active site, at the bottom near Trp84, to the peripheral
anionic site, at the top near Trp279 (see Figures 3 and 4).
The 3D structure of the complex shows more detail of the
AChE structure than the starting native model (Protein
Data Bank [PDB] code 2ACE). Specifically, residues 2
and 3, at the N terminus, and the 484–490 loop, which
were not seen in the original model, can be discerned. In
addition, it was possible to model the proximal N-acetyl-
glucosamine (NAG) moiety at four out of five putative
glycosylation sites [27], namely at residues Asn59, Asn416
(where two moieties could be fitted), Asn457 and Asn533.
An analysis of the quality of the refined model is summa-
rized in Table 1.
All three segments of E2020 interact with AChE
As seen in Figure 5, E2020 makes principal interactions
along the active-site gorge of the enzyme through its three
major functional groups: the benzyl moiety, the piperidine
nitrogen, and the dimethoxyindanone moiety. These inter-
actions involve discrete water-mediated contacts that seem
to be crucial for binding and specificity.
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Figure 2
Initial difference electron-density map, contoured at 4.5σ, based on the
native TcAChE structure (PDB code 2ACE) and the diffraction data for
the E2020–TcAChE complex.
Figure 1
Schematic drawing of E2020, (R,S)-1-benzyl-
4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl-
piperidine. *C8 is the chiral carbon.
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Structure
Interactions at the bottom of the gorge
Near the bottom of the gorge, one face of the benzyl ring
displays classic parallel pi–pi stacking with the six-membered
ring of the Trp84 indole, similar to the interaction with
THA [28]. It thus occupies the binding site for quaternary
ligands [28,29], which was also modeled for the quaternary
group of the natural substrate, ACh [17,26]. The ring-to-ring
distances range from 3.7 Å between Trp84 Cδ2 and E2020
C19 to 4.4 Å between Trp84 Cε2 and E2020 C22.
On the opposite face, the benzyl group makes a classic
aromatic hydrogen bond (H bond) [30,31] with a water
molecule (WAT 1160), with distances to the ring carbons
of 3.5 Å–3.7 Å. This solvent molecule is held firmly, as
assessed by a below-average temperature factor, by an
H bond to another solvent molecule (WAT 1161) in the
‘oxyanion hole’ and to WAT 1159 (see below). WAT 1161
is another example of a tightly bound water molecule with
a relatively low temperature factor; it makes an H bond
with the residues of the oxyanion hole, namely with
Gly118 N, Gly119 N and Gly201 N, as well as with
Ser200 Oγ. Finally, the kinetic evidence showing that
E2020 binds to the free and the acylated forms of AChE
[32] is corroborated by our observation that E2020 does
not interact with the catalytic triad. Other interactions are
shown schematically in Figure 5.
Interactions in the middle of the gorge
In the constricted region, halfway up the gorge (Figures 3
and 4), the charged nitrogen of the piperidine ring makes
a cation–pi interaction [33,34] with the phenyl ring of
Phe330, with distances of 3.9 Å–4.5 Å between the nitro-
gen and the ring carbons. The orientation of the phenyl
ring is similar to that seen in the complex of decametho-
nium (DECA) with TcAChE (DECA–TcAChE; PDB code
1ACL) [28]. The ring nitrogen also makes an in-line 2.9 Å
H bond with WAT 1159, which, in turn, makes H bonds
with Tyr121 OH, with WAT 1158 and with WAT 1160
(see above). As already mentioned, the binding site for the
quaternary nitrogen of ACh, and for homologous ligands,
is the indole ring of Trp84 [17,26,28]. These data suggest
that Phe330 may serve as an additional quaternary binding
site, midway down the gorge, between the peripheral site
and the anionic subsite of the active site.
Interactions at the entrance to the gorge
At the top of the gorge the indanone ring stacks against the
indole ring of Trp279, in the peripheral binding site, by a
classical pi–pi interaction. Specifically, E2020 C1, C2, C6,
O25, C26, O27 and C28 stack against the six-membered
ring of Trp279, with distances of 3.7 Å–4.2 Å. WAT 1249
lies in the plane of the indanone moiety, and H bonds to
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Figure 3
E2020 binds along the active site and interacts with the ‘peripheral
anionic’ subsite at the top and with the ‘anionic’ subsite at the
bottom. E2020 is displayed in green semi-transparent CPK and ball-
and-stick representation, solvent molecules are shown as lilac balls,
catalytic triad residues are in orange, binding residues are shown as
purple sticks, and the solvent-accessible surface of the gorge is
shown as a brown net.
Figure 4
The E2020–TcAChE complex. Ribbon diagram showing the complex
of the drug bound to the enzyme.
the methoxy group of E2020 O25; it is also H-bonded to
Glu185 Oε1 of the symmetry-related crystal-lattice copy of
the enzyme. The carbonyl on the five-membered ring of
the indanone only interacts with AChE via edge-on van der
Waals contacts with the aromatic rings of Phe331 and
Phe290. It also makes indirect contact, via WAT 1254, with
Phe288 N. This finding might initially appear puzzling in
view of the fact that a homolog of E2020, which lacks this
carbonyl, was reported to be inactive [15]. Our structure-
based suggestion is that the van der Waals contacts made by
the carbonyl function help orient the indanone moiety to
make a favorable interaction with the indole ring of Trp279.
In the homolog which lacks this carbonyl function, the
indanone moiety would be less constrained and would con-
sequently make a poorer interaction with Trp279.
AChE selects the R form of E2020
The reported pharmacological studies on (R,S)-E2020
emphasize that both enantiomers are active; they have
similar pharmacological profiles [22,32], but show ~fivefold
difference in binding affinity for AChE: Ki = 3.35 nM (R),
17.5 nM (S) [32]. Although we used the racemate in our
crystallographic study, we were not, therefore, surprised to
see only the R form in the experimental electron-density
maps (see Figure 6). The observed conformation is very
similar, if one allows for permitted adjustments of dihedral
angles, to the energetically minimized E2020 conformation
calculated with the InsightII package [35], and it is also
similar to the ‘small molecule’ crystal structure of the pure
R enantiomer (T Steiner, R Boer and J Kroon, personal
communication).
E2020 analogs
Variation of the inhibitor backbone
Kawakami et al. [14] showed that at least two rotatable
bonds on each side of the piperidine are needed to yield
the high affinity displayed by E2020 and some of its
analogs. We can now corroborate this observation by
showing that the two aromatic moieties of E2020 interact
closely with Trp84 and Trp279, while still maintaining the
Phe330–piperidine-nitrogen interaction. This array of
interactions calls for flexibility along the backbone of the
inhibitor. The number of rotatable links is also important
for optimal positioning of the aromatic systems of the
inhibitor against their enzyme counterparts. Indeed, when
two to three additional rotatable bonds are added between
the indanone and the piperidine, affinity further increases
(Table 2, lines 20–22), whereas adding rotatable bonds
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Table 1
Data collection and refinement statistics.
Data collection
Detector Raxis-II
Source/wavelength (Å) Rigaku FR300 (50 mA, 50 kV), 1.54184 (Cu K
∝
)
Resolution range (Å) 30.0–2.5
Number of reflections 34,264
Completeness (%) 98.1
Redundancy
value 0 1 2 3 4 >5
accumulated (%) 1.9 15.7 44.3 33.4 4.5 0.2
I/σ
value 0 1 2 3 5 10 20 >20
accumulated  (%) 5.5 14.2 23.4 30.7 41.2 57.6 78.1 20.0
Rsym (%) 5
Refinement
Number of protein non-H atoms 4255 = 2137 mainchain + 2118 sidechain
Number of hetero non-H atoms
Water molecules 396
Carbohydrate 70 = 5 × 14 in five NAG groups
Inhibitor 28 in one E2020 group
Resolution (Å) 2.5
Rwork (%) 18.8 (no σ cutoff)
Rfree (%) 22.9 (no σ cutoff)
B factor (Å2); Average / σ / Mininum / Maximum
Protein 28.0 / 12.5 / 2.0  /90.2
Inhibitor 20.4 / 4.8 / 13.2 / 31.6
Carbohydrate 47.6 / 15.0 / 14.5 / 74.5
Water molecules 37.2 / 14.7 / 2.2 / 86.7
Rmsd bond length (Å) 0.005
Rmsd bond angle (°) 1.2
Rmsd dihedral angle (°) 22.9
Rmsd improper angle (°) 0.98
Rsym = ΣIi–<I>/ΣIi. Rwork = Σ|Fo|–|Fc|/ΣFo. Rfree is calculated using 2000 random reflections.
between the piperidine and the benzyl ring lowers it
(Table 2, line 19). This distinction between adding rotat-
able bonds ‘above’ and ‘below’ the piperidine is likely to
be based on the distances between Phe330 and either
Trp84 or Trp279. Any change in the length of the spacer
between Phe330 and Trp84 would weaken the inter-
actions of the inhibitor with those sidechains. However,
limited elongation of the indanone–piperidine link might
allow more overlap of the indanone’s aromatic system with
that of Trp279.
Variation of the benzyl moiety
E2020 is highly sensitive to substitutions on the benzyl
moiety, as found by Kawakami and coworkers [14], who
noticed a general preference for substitution at the meta
(E2020 C20, C22) positions in comparison to the ortho
(E2020 C19, C23) and para (E2020 C21) positions (see
Table 2). Although these solution studies could not differ-
entiate between the two possible ortho/meta substitutions, it
can been seen from the crystal structure how each position
would experience different environments with respect to
the lining of the gorge and the structural solvent molecules
within it. In general there is little space left between the
benzyl ring and the gorge surface (Figures 3 and 4), which
may explain the sensitivity to substitutions of this moiety.
The ring carbon at the para position is 3.2 Å from
Glu199 Oε1; thus a substituent must be both small and able
to make an H bond. Indeed, according to Kawakami et al.
[14], an analogue with a hydroxyl at this position binds with
higher affinity than the corresponding fluorine derivative
(Table 2, lines 9–12). A substituent at the meta position,
E2020 C22, will point to a very small space left between
Glu199, His440 and Ser200 (the last two of which are
members of the catalytic triad). The other meta position, at
E2020 C20, points to a wider space partially bordered by
Gly117 and the ‘oxyanion hole’. In our structure, this space
is mostly occupied by solvent molecules and can accommo-
date a small, preferably negatively charged, substituent
(Table 2, lines 5–7). A cyclohexane in place of a benzyl ring
cannot make a pi–pi stacking interaction with Trp84, result-
ing in reduced affinity (Table 2, line 18).
Variation of the piperidine moiety
A piperazine in place of piperidine lowers the affinity of
the resulting analog by ~19-fold (Table 2, line 3), whereas a
piperidine with a nitrogen at the opposite position (in place
of E2020 C10) lowers the affinity by ~90-fold (Table 2,
line 2). A piperazine, although containing a nitrogen at a posi-
tion suitable for binding with Phe330, possesses a different
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Figure 5
Major interactions between E2020 and TcAChE. Classical H bonds
are shown as dashed lines, aromatic stacking and aromatic H bonds
are shown as black lines connecting matching colored planes.
Figure 6
Two views of E2020 modeled in the initial difference Fourier map.
Only one enantiomer is observed in the crystal structure. The shape
of the electron density around the chiral carbon and the carbonyl
clearly resolve the R/S ambiguity. ‘Side’ and ‘front’ views of E2020
are shown modeled in the initial difference electron-density map
contoured at 4.5σ.
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Table 2
E2020 analogs.
Analog number Constant Variable R Inhibition of AChE IC50 (nM) [14]
1. CH2 R
CH3O
CH3O
CH2
O
N
(E2020)
5.7
2.
N
480
3.
N N
94
4. CH2 N R
CH3O
CH3O
O
CH2
CH3
10
5. CH2
F
1
6. CH2
CH3
2
7. CH2
NO2
4
8. CH2
OMe
220
9.
CH2 OH
1.8
10.
CH2 F
9.5
11.
CH2 CH3
40
12.
NO2CH2
100
charge distribution, whereas a piperidine with a nitrogen at
the opposite position does not allow a quaternary-pi inter-
action with Phe330 to occur.
Variation of the indanone moiety
In general, substitutions on the indanone moiety have a
smaller effect than substitutions on the benzyl group [15].
This is consistent with our crystal structure, as the indanone
moiety is located in the wide section of the funnel-like
entrance to the gorge. Thus, some sites of substitution
would point outwards towards the solvent, whereas others
would point into the central region of the gorge. However,
substitution on the same edge as the carbonyl group
(C7 O24), which is juxtaposed to the wall of the gorge,
would disrupt the parallel stacking to Trp279. This is con-
sistent with the observation of Cardozo et al. [15] that a
cyano substitution on E2020 C6 produces a relatively poor
inhibitor. Suitable substitutions on the other edge of the
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Table 2 continued
13. CH2
F
9.5
14. CH2
MeO
80
15. CH2
O2N
160
16.
CO
>10,000
17.
H
5400
18.
CH2
8.9
19.
CH2CH2
180
20. -R- N CH2
OH3C
OH3C
O
0.9
21. 1.5
22. 3.0
ring (namely E2020 C1, C2, C3 and C9) would be expected
to have little effect or, possibly, result in improved affinity. 
Comparison of the E2020–TcAChE complex with other
complexes
The structures of native TcAChE and of six different com-
plexes were overlaid according to their Cα positions,
namely native AChE (PDB code 2ACE) [36], and the com-
plexes with tacrine (THA; PDB code 1ACJ) [28], DECA
(PDB code 1ACL) [28], m-(N,N,N-trimethylammonio)tri-
fluoroacetophenone (TMTFA; PDB code 1AMN) [29],
huperzine (HUP; PDB code 1VOT) [36], edrophonium
(EDR; PDB code 2ACK) and E2020 (PDB code 1EVE).
Two issues arise from comparison of these structures: the
role of Phe330, and the possible significance of structurally
conserved solvent molecules within the gorge. 
Phe330 as a ‘swinging gate’
As seen in Figure 7, Phe330 adopts a wide range of con-
formations in the complex structures analyzed. These con-
formations can be assigned, primarily based on their χ1
values, to three different groups. First, native, TMTFA,
HUP and EDR (χ1 = –162°, –174°, –171° and –177°,
respectively). Second, THA (χ1 = 157°). Third, E2020 and
DECA (χ1 = –130° and –117°, respectively). In group 1,
Phe330 adopts a similar conformation in the native enzyme
and in the complexes with ligands that bind near the bottom
of the gorge, with the exception of THA. This ligand
defines Group 2, in which χ1 and χ2 of Phe330 change so as
to permit its phenyl group to stack on top of the ligand, thus
forming a ‘sandwich’ with the indole of Trp84. The
common feature of Group 3 is the gorge-spanning ligand
that forces the aromatic ring of Phe 330 to swing out of the
way towards the gorge wall. It is also of interest that the
THA–TcAChE complex displays a different conformation
for the indole group of Trp279 relative to native AChE and
the other complexes (χ2 value of 30° versus about 90° for
the others). This provides some support for structural cou-
pling along the gorge between the anion subsite of the
active site and the peripheral anionic site, as suggested by
Shafferman and coworkers [37]. The conformational flex-
ibility displayed by the sidechain of Phe330, contrasted
with the relative rigidity of the other sidechains lining the
gorge, supports the notion that it contributes to the sig-
nificantly higher catalytic activity of AChE relative to
BChE, which lacks this residue. Site-directed mutagene-
sis studies [38,39] showed that elimination of this aro-
matic sidechain does not affect the Km for both charged
and uncharged ligands. It does, however, have a signifi-
cant effect on kcat, which decreases ~fourfold for cationic
substrates, although it increases ~twofold for uncharged
substrates. Thus, via the quaternary-pi electron interaction
clearly seen in the E2020 complex, it may serve to guide
ACh towards the active site, while simultaneously isolat-
ing the reaction center from the rest of the gorge. In fact,
substrate traffic down the gorge may actually occur con-
comitantly with a swinging movement of Phe330. Similar
ideas have been proposed on the basis of molecular dynam-
ics studies [40,41].
The solvent
In the E2020–TcAChE complex, 25 ordered waters can be
seen within the gorge. If one overlays this structure with
that of the native enzyme and of five other complexes, as
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Figure 7
Overlay of native TcAChE and six complexes.
The flexibility of Phe330 in comparison with
the rigidity of the rest of the gorge can be
seen. Backbone trace and key residues are
represented by thin lines, Phe330 by thick
lines and inhibitors are shown in ball-and-stick
representation. *A ChemDraw representation
of ACh is shown for purposes of comparison.
shown in Figure 7, one can see that most of these waters are
conserved (G Koellner, GK, IS, JLS and T Steiner, unpub-
lished results). In the E2020 structure, in fact, only three of
the conserved waters seen in the native enzyme are dis-
placed. From this one can conclude that a large ligand, such
as E2020, fits into the gorge by displacing primarily the
unbound solvent molecules. Many of the conserved waters
appear to adhere to the gorge wall and may, perhaps, be
considered as an integral part of the structure of the gorge
rather than as voids. This may be especially important in
relation to drug design (see below), as well as in molecular
dynamics studies. It should also be noted that water mol-
ecules not observed in the native structure are seen in the
E2020 complex, where they bridge between the inhibitor
and the enzyme. Specifically WAT 1159, WAT 1160 and
WAT 1254 (see Figure 5) are ‘novel’ structured waters not
previously seen in the native structure, while five ordered
waters in the native structure are displaced.
Structure-based modification of E2020
Chemical modification of an already effective drug can
often improve its pharmacological profile in terms of affin-
ity and specificity. The calculated ‘empty’ spaces within
the gorge (see Figures 4 and 8), which are revealed in the
3D structure of the E2020–AChE complex, point to candi-
date sites on the inhibitor where added functions might
indeed enhance its pharmacological profile. Separation of
enantiomers, which are chemically indistinguishable by
non-chiral environments, is difficult, inefficient and costly.
In the case of E2020, we suggest that introduction of a
second chiral center, with concomitant generation of a
diastereomer system, would facilitate isolation of an active
component from the mixture so generated [42,43]. Inspec-
tion of the empty spaces left within the aromatic gorge by
the ordered solvent and by E2020 reveals a finger-shaped
void at the acyl-binding pocket. This pocket, defined by
Phe288, Phe290, Phe331 and Trp233, could envelop a
non-polar substituent branching from the piperidine ring at
position E2020 C12. Such a substitution, which would fit
into the ‘acyl pocket’, combined with the existing chiral
center, would produce a separable diastereomeric inhibitor.
The recent observations concerning the effect of peripheral-
site ligands on AChE-enhanced amyloid deposition [10],
mentioned above, raise the possibility that E2020, which
our data clearly show as stacking against Trp279, might
also moderate the rate of fibril formation. Many of the com-
pounds synthesized and tested by the Eisai company
involved modification of this segment of the molecule
[15,16]. Nevertheless, it should be borne in mind that the
screening that they carried out involved assessment of
affinity for AChE, together with selectivity for AChE rela-
tive to BChE, but not a possible effect on amyloid fibril
assembly or deposition.
Biological implications
Acetylcholinesterase (AChE), the enzyme that hydrolyzes
the neurotransmitter acetylcholine (ACh) at cholinergic
synapses [44], is the target of the first generation of drugs
for the treatment of Alzheimer’s disease. E2020 is the
second drug targeted at AChE approved for use by the
FDA for treatment of this condition. As design and devel-
opment of the drug preceded the determination of the 3D
structure of AChE, it was of interest to use X-ray crystal-
lography to clearly delineate the structural factors govern-
ing its selectivity and specificity. This was particularly
important because E2020 bears no structural resemblance
to other anticholinesterase drugs either approved or under
advanced clinical trial, such as tacrine, huperzine A and
ENA-713 [45]. Our study shows, a posteriori, that the
design of E2020 took advantage of several important fea-
tures of the active-site gorge of AChE to produce a drug
with both high affinity and a high degree of selectivity for
the enzyme, but not for butyrylcholinesterase (BChE).
The high affinity results from interaction of E2020 with
the aromatic residue involved in recognition of ACh at
the bottom of the gorge, Trp84, with a second aromatic
residue at the midpoint of the gorge, Phe330, and with a
third residue, Trp279, which is part of the peripheral
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Figure 8
‘Empty’ spaces, where no ordered solvent molecule is observed, can
accommodate a substituent branching from the inhibitor. Voids within
the gorge are displayed in yellow, the solvent-accessible surface of
E2020 is in purple, the solvent-accessible surface of the gorge is
shown as a brown net, the CPK model of the solvent molecules is in
lilac, residues near voids are in light blue, and the catalytic triad is
represented by orange sticks.
anionic site at the top of the gorge. The fact that these two
latter residues are conserved in AChE, but absent in
BChE, leads to the selectivity that may be an important
clinical consideration, as inhibition of BChE may cause
potentiating site effects. Our study also delineates voids
within the gorge of AChE that are not occupied by E2020,
which could serve as sites for modification of E2020 to
produce drugs with greater affinity and/or selectivity for
AChE. It is worth noting that the 3D structure of Torpedo
california AChE (TcAChE) is very similar to those of
both mouse [46] and human AChE [47]. Thus, the con-
clusions drawn from the structure of the E2020–TcAChE
complex should be valid for the mammalian enzyme.
Finally, analogs of E2020 are under consideration as a
possible new class of insecticides [48]. The structure of
Drosophila AChE has recently been solved to 2.7 Å reso-
lution in our laboratory [49] (M Harel, GK, H Green-
blatt, L Toker, W Mallender, TL Rosenberry, T Lewis,
IS and JLS, unpublished results). Although Drosophila
AChE shares overall structural features with the Torpedo
and human enzymes, it also displays marked differences.
Our combined knowledge of the vertebrate and inverte-
brate enzymes should be valuable in developing effective
insecticides that combine high specificity for the insect
enzyme with low toxicity in humans.
Materials and methods
Protein preparation and crystallization
TcAChE was purified and crystallized as described previously [36].
E2020, as the hydrochloride salt of the pure racemate, was a generous
gift from Dr BP Doctor (Division of Biochemistry, Walter Reed Army Insti-
tute of Research, Washington, DC). TcAChE crystals of trigonal morphol-
ogy were soaked for five days at 4°C in mother liquor (36% PEG 200,
10 mM NaCl, 50 mM MES, pH 5.8) containing ~10 mM (R,S) E2020. 
X-ray data collection and processing
The X-ray data were collected from a single crystal that was flash cooled
in a 100K nitrogen stream after exchanging the exterior solvent drop with
a coating of Exxon high viscosity motor oil [50]. Data were collected in-
house, at the Weizmann Institute, utilizing a Rigaku RAXIS-II image-plate
system, and a Rigaku FR300 X-ray generator employing a copper target
set at 50 mA and 50 kV. The data-collection scheme was optimized by
use of the software STRATEGY [51], and consisted of 81 frames of
0.5° rotation and 30 min exposure time each. The diffraction data were
extracted from the frames using the software package HKL [52], result-
ing in a 98.1% complete dataset of 34,264 reflections, overall Rsym of
5% and overall I/sigma ratio 13.8 (see Table 1).
Model refinement and analysis
The structure was refined using the starting model of native TcAChE
(PDB code 2ACE) with the program X-PLOR version 3.851 [53]. Refine-
ment employed all 30–2.5 Å data. Following overall anisotropic B-factor
and bulk-solvent corrections, the structure was first refined as a single
rigid body. Subsequently, refinement was carried out on individual atoms,
with restraints, using simulated annealing alternating with positional and
temperature-factor refinement. The model was fitted to the observed
electron density using the software O [54] on a Silicon Graphics work-
station. This program was also used to overlay analogous models by
least-squares minimization of Cα positions. The intermediate and final
models were analyzed using the software OOPS [55], PROCHECK [56]
and WHATCHECK [57], and corrections to the model based on these
analyses were implemented (see Table 1). Voids of minimal continuous
volume of one spherical cubic angstrom were calculated using the soft-
ware SurfNet [58], between the inhibitor molecule as one entity and the
protein and solvent molecules, taken together, as a second entity.
Accession numbers
The PDB code of the E2020-TcAChe complex is IEVE.
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